In recent years it has become apparent that in neuroblastoma ATRX mutations define a distinct patient subgroup that are mutually exclusive with MYCN amplification, associated with older age at diagnosis and a chronic progressive disease course [4,8]. This evidence concerns the gene ATRX and neuroblastoma.